AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06006494 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic
Description: We can think of aerobic exercise as a low-intensity long-term activity using large muscle groups (between 60-80% of maximal heart rate). For example; includes activities such as walking, cycling, jogging, aerobic dancing, swimming.~An average of 50 minutes of exercise per day will be required, 3 days a week.
Study NCT05664139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Adenovirus Type 5 Injection,Camrelizumab,Nab-paclitaxel
Description: Recombinant Human Adenovirus Type 5 Injection:①the longest diameter of the lesion≥10mm and≤40mm, inject 1ml into the tumor each time;②the longest diameter of the lesion≥40mm and≤80mm, inject 2ml into the tumor each time. planned injections at D1. Every 3 weeks is a period, a total of 4 cycles; if there are visceral and superficial lesions at the same time, the injection lesions will be selected by the investigator based on possible benefits.~Camrelizumab:200mg/time.Intravenous within 48 hours after injection of recombinant human adenovirus type 5 injection. Every 3 weeks is a period, and the treatment is continued until the subject has disease progression or unacceptable toxicity or death.~Nab-paclitaxel:260mg/m2, D1, every 3 weeks as a period, a total of 4-6 cycles (determined by the investigator), or continue treatment until the subject has disease progression or Intolerable toxicity or death.
Study NCT02365974 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Stimulation
Description: TENS will be applied in the cervicothoracic ganglion region located between the C7 and T4 vertebral processes for 40 minutes three times weekly for a total of four weeks. The intensity in milliamps will be adjusted depending on the sensitivity of each individual patient.
Study NCT02365974 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: No Transcutaneous Electrical Stimulation
Description: The sham group will be submitted to the procedure to fit the stimulation equipment. without be submitted to stimulation.
Study NCT06109506 — intervention group
Intervention type: PROCEDURE
Intervention: Conservative treatment with antibiotics and eventual percutaneous image-guided drainage of the abscess
Description: Patients with acute diverticulitis and abscess formation are commonly treated with a conservative approach that includes endovenous antibiotics and, for abscesses > 4-5 cm, percutaneous image-guided drainage.
Study NCT05721443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib+cetuximab
Description: The dosing regimen for cetuximab combined with dalpiciclib is: the starting dose of cetuximab is 400 mg/m2, titrated over 120 minutes, and the titration rate should be limited to 5 ml/min. A maintenance dose of 250 mg/m2, titrated over not less than 60 minutes, with pretreatment with H1 receptor blocker desensitization prior to dosing, administered once weekly.~The recommended dose of dalpiciclib is 150 mg once daily for 21 days, followed by 7 days of discontinuation (3/1 dosing regimen) for a 28-day treatment cycle. Take the drug at approximately the same time each day. If the patient vomits or misses a dose, the dose should not be made up that day. The next dose should be taken as usual.~Subjects will continue treatment with cetuximab in combination with dalpiciclib until termination criteria are met.
Study NCT05878782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MCRO+Occupational therapy
Description: Experimental group A will combine the assessment of occupational problems (MCRO) and an occupational therapy intervention.
Study NCT05878782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MCRO without intervention
Description: Experimental group B will have only the MCRO assessment because the occupational problems assessment alone (without intervention) could improve quality of life and occupational performance outcomes, according to the Nielsen, 2019 study
Study NCT04186676 — intervention group
Intervention type: OTHER
Intervention: MINOCA registry
Description: Prevalence, demographics, clinical profile, anginal status, presence of cardiovascular risk factors, management and outcomes
Study NCT04186676 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CCTA Phenotypes
Description: 1. Complete normal coronary arteries~2. Diffuse non-obstructive coronary artery disease~3. Non-obstructive high-risk plaques~4. Myocardial bridges
Study NCT04978610 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Virtual Acceptance Commitment Therapy
Description: For a period of 6 continuous weeks, participants will meet weekly in a virtual group ACT session with a licensed psychologist hosted on a secure, HIPAA compliant, Zoom account. Each session is 1.5 hours will focus on one ACT concept including Acceptance, Values, Mindfulness, Cognitive Defusion, Experiential Avoidance, and Willingness and Committed Action. Subjects will be given the opportunity to share their thoughts as well as their responses to the exercises at various points throughout the sessions.~At the beginning of each session, each participant will be required to fill out a short survey on their stress and pain the preceding week. Participants in the control group will not complete weekly measures. All measures will be completed online via a REDCap survey web link. Follow up measures will mirror initial baseline measures in order to measure the within group and between group changes in study outcomes.
Study NCT04978610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Acceptance Commitment Therapy
Description: For a period of 6 continuous weeks, participants will meet weekly in a virtual group ACT session with a licensed psychologist hosted on a secure, HIPAA compliant, Zoom account. Each session is 1.5 hours will focus on one ACT concept including Acceptance, Values, Mindfulness, Cognitive Defusion, Experiential Avoidance, and Willingness and Committed Action. Subjects will be given the opportunity to share their thoughts as well as their responses to the exercises at various points throughout the sessions.~At the beginning of each session, each participant will be required to fill out a short survey on their stress and pain the preceding week. Participants in the control group will not complete weekly measures. All measures will be completed online via a REDCap survey web link. Follow up measures will mirror initial baseline measures in order to measure the within group and between group changes in study outcomes.
Study NCT06006494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic
Description: We can think of aerobic exercise as a low-intensity long-term activity using large muscle groups (between 60-80% of maximal heart rate). For example; includes activities such as walking, cycling, jogging, aerobic dancing, swimming.~An average of 50 minutes of exercise per day will be required, 3 days a week.
Study NCT06006494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistant
Description: Resistance exercises are the whole of the exercises in which effort is made against the weight and the weight is lifted. Exercises with therabands, dumbbells or body weight will be given. The exercises will be done 2 days a week for an average of 30-40 minutes.
Study NCT06006494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: yoga
Description: Yoga is basically breathing exercises, warm-up exercises, relaxation, It is a session consisting of movements and relaxation exercises.movements are performed by standing in a fixed posture for 15 seconds to 2 minutes in a certain posture, they are postures for both strengthening, stretching and balance. Yoga practice will be done 2 days a week for an average of 40 minutes.
Study NCT06358846 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-care behavior to promote foot care through educational guidance among individual with diabetes
Description: Apart from physician consultation, individuals will received structured training of how to care their foot to avoid ulcer and inflammation.
Study NCT05146739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV and IT
Study NCT05146739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT05146739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Give PO or IV
Study NCT05146739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple Intrathecal Chemotherapy
Description: Given IT
Study NCT05146739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uproleselan
Description: Given IV
Study NCT05127850 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consultation audio recording app
Description: Smartphone or tablet mobile application which allows for voice recording
Study NCT03928808 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)
Description: Nasogastric administration of OpenBiome 25 g/mL solution administered nasogastrically once weekly for 4 consecutive weeks
Study NCT04504825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAEL-101
Description: The investigational product, CAEL-101, is formulated as a sterile liquid solution of protein plus excipients for dilution in a single-use, stoppered, glass vial. Each 10 mL vial contains 300 mg of CAEL-101 at a concentration of 30 mg/mL. CAEL-101 will be diluted with commercially available 0.9% Normal Saline.
Study NCT04504825 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Commercially available 0.9% Normal Saline will be used as the placebo.
Study NCT04504825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen
Description: According to institutional standard of care.
Study NCT04504825 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen
Description: According to institutional standard of care.
Study NCT06223750 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: population-based screening for chronic kidney disease
Description: Randomized controlled trial that uses an integrated health platform for eligibility and outcome assessments
Study NCT06644469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynatronics VF5 Model vibration platform
Description: The Dynatronics VF5 Model vibration platform is a specialized therapeutic device designed for rehabilitation and wellness applications. Utilizing advanced vibration technology, it provides whole-body vibration therapy that can enhance muscle strength, improve flexibility, and promote overall physical well-being. The platform features adjustable frequency and amplitude settings, allowing customization based on individual needs. Its user-friendly interface and robust, durable design make it suitable for both clinical and mobile therapy settings. Additionally, the compact and portable nature of the VF5 facilitates easy storage and transport, while safety features such as non-slip surfaces ensure user protection.
Study NCT06644469 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Dynatronics VF5 Model vibration platform
Description: Placebo intensity with vertical vibration of 0.2 mm
Study NCT06169137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Time-Restricted Eating
Description: Participants will be provided all meals to consume within a 6-hour timeframe (9:30-3:30p)
Study NCT06169137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional dietary regimen (12-hr, 9:30a-9:30p)
Description: Participants will be provided all meals to consume within a 12-hour timeframe (9:30a-9:30p)
Study NCT05901012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N,N-Dimethyltryptamine
Description: DMT will be administered using a vaporizer device in a placebo-controlled, double-blind, randomized, monocentric clinical trial design.
Study NCT05901012 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: DMT will be administered using a vaporizer device in a placebo-controlled, double-blind, randomized, monocentric clinical trial design.
Study NCT05398952 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory investigations
Description: Laboratory investigations correlated with symptoms and imaging results
Study NCT06277271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarette
Description: Participants will be supplied with an e-cigarette along with a 4-week supply of e-liquid. Participants will receive training on how to use the device and practice puffing with the e-cigarette during the research visit. They will be instructed to self-regulate administration according to their craving and withdrawal symptoms and to refrain from using other nicotine and tobacco products.
Study NCT06228924 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: TN-401
Description: TN-401 is a recombinant adeno-associated virus serotype 9 (AAV9) gene therapy containing Plakophilin-2 (PKP2) transgene. It is a single (one-time) intravenous dose.
Study NCT06442098 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAMP SMART Literacy Summer Camp
Description: Multimodal approach to reading intervention
Study NCT05189327 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Non-interventional study
Study NCT05259150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health for Hearts United Planning for Health
Description: Participants (health leaders) receive trainings (three entitled Take Charge of Your Health, Eat Better, \& Move Around More) and plan for their health ministry and cardiovascular health program to congregants.
Study NCT05259150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health for Hearts United Preparing for Health
Description: Research participants (church congregants) receive cardiovascular health programming prepared by health leaders that includes the following best practices: Individual Goal Setting, Training, Culturally-tailored Materials, Monitoring Tool \& Recognition.
Study NCT05097118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Versus Bupivacaine
Description: Drugs Ketamine versus Bupivacaine
Study NCT05271838 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium acetate mixture (30 mmol/ml)
Description: Patients with a magnesium retention test >25% and randomized to intervention receive magnesium acetate oral mixture (30 mmol/ml) 20 ml x 3/day for a period of three weeks.
Study NCT05271838 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-protein diet (2 g/kg/day)
Description: Nutritional counseling and protein supplementation to establish an intake of 2 g protein kg/day during admission and three weeks after discharge.
Study NCT05063305 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The probiotic to be used in the study is in capsule form and consists of 12 bacterial strains and 10-billion colony forming unit (CFU). The product consists of the following bacterial strains and species: Bifidobacterium infantis ATCC SD 6720, Bifidobacterium bifidum ATCC SD 6576, Bifidobacterium breve ATCC SD 5206, Bifidobacterium lactis ATCC SD 5220, Bifidobacterium longum ATCC SD 5588, Lactobacillus acidophilus DSM 32754, Lactobacillus casei ATCC SD5213, Lactobacillus paracasei ATCC SD 5275, Lactobacillus plantarum ATCC SD 5209, Lactobacillus reuteri ATCC SD 6689, Lactobacillus rhamnosus ATCC 53103, Lactobacillus salivarius ATCC SD 5208) in combination with the prebiotic, xylooligosacharide (XOS).
Study NCT05063305 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo, that will be indistinguishable in appearance to the probiotic, will be provided to half of all study participants for the length of the trial. It will contain the following ingredients: Microcrystalline cellulose, magnesium stearate, a vegetarian capsule, and silicon dioxide. The probiotic will be manufactured by MeriCal.
Study NCT05259150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health for Hearts United Delivery of Health
Description: The Organization (church) uses best practices to implement Heart Health activities (annual plans, achievements, plans for the year and practices).
Study NCT05259150 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health for Hearts United Comparison Group Health Ministry Development
Description: Participants (health leaders) have meetings to develop the health ministry. Research participants (church congregants) do not receive cardiovascular health program.
Study NCT02410421 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Functional magnetic resonance imaging used to individualize rTMS protocol using robotic coil positioning
Study NCT02410421 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging used to individualize rTMS protocol using robotic coil positioning
Study NCT05828849 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigation, compensation, and personalization
Description: The study intervention is composed of navigation, compensation, and personalization. Navigation refers to reducing barriers posed by fragmentation of health and social systems. Compensation refers to reimbursement of out-of-pocket expenses to offset dependent care, time costs, and travel expenditures necessary to access care for the different conditions and goals of the intervention. Personalization refers to preventative interventions that are personalized based on individual for potential benefit.
Study NCT06255821 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure
Description: One-session of graded in-vivo exposure with a spider. Each task is first modeled by the experimenter. Prior to the exposure, participants receive psychoeducation on anxiety and phobias.
Study NCT05502146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Noradrenaline Bitartrate
Description: An intravenous bolus of norepinephrine 6 mcg will be administered for management of maternal hypotension.
Study NCT05502146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: Subarachnoid block will be performed using Bupivacaine hydrochloride (2.5 mL)
Study NCT05502146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Noradrenaline Bitartrate
Description: An intravenous bolus of norepinephrine 8 mcg will be administered for management of maternal hypotension.
Study NCT05502146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Subarachnoid block will be performed using Bupivacaine hydrochloride (2.5 mL)
Study NCT03486444 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Phillips Lumify Diagnostic Ultrasound System
Description: portable ultrasound device
Study NCT03486444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveys
Description: surveys assessing perception of ultrasound
Study NCT05402540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STRAIN COUNTER STRAIN GROUP
Description: Strain Counterstrain Technique in combination with conventional physiotherapy (Hot pack, Codmans exercises, active assisted exercises, Pendulum exercises, Finger Ladder Exercise, Maitland mobilization of shoulder joint.~Therapist palpate surrounding and opposing tissues to locate trigger point by using one or two finger pads to monitor fasciculation and MTrP.~Hold the POC (position of comfort) until fasciculation decreases significantly or ceases. Average positions hold time while pressure is 90 s to 3 min.~Release tissue or joint slowly and reassess. Each patient will receive total 6 sessions (3sessions/week) over a period of 2 weeks.~Assessment would be done on baseline and after every three sessions.
Study NCT05402540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACTIVE RELESAE TECHNIQUE GROUP
Description: Active Release Technique in combination with conventional physiotherapy (Hot pack, Codmans exercises, active assisted exercises, Pendulum exercises, Finger Ladder Exercise, Maitland mobilization of shoulder joint.~The targeted muscle will be palpated while the therapist will looks for localized tenderness or trigger points with referred pain elicitation.~With the thumb therapist will relieve the trigger point. In ART the particular muscle is taken from shortened to lengthened position or from lengthened to shortened position.~Duration of treatment will be 8-15 minutes. Each patient will receive total 6 sessions (3sessions/week) over a period of 2 weeks.~Assessment would be done on baseline and after every three sessions.
Study NCT04629781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel micellar
Description: There will be three dose levels, 1-3, with each level consisting initially of a cohort containing 3 patients. One additional dose level, dose level -1, shall be allowed in the event that dose level 1 is considered too toxic
Study NCT05502744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy is the standard treatment for acute cholecystitis due to the advantages of small wounds, less use of abdominal drains , less need for antibiotics and analgesics and less postoperative hospital stay time.Laparoscopic cholecystectomy in acute cholecystitis may be performed as soon as begging of the symptoms called emergency or urgent and maybe scheduled in advance after controlling acute attack after 6-8weeks called elective.
Study NCT05955001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 5mg / Placebo
Description: Patients after Holmium laser Enucleation of Prostate (HoLEP) will receive single daily dose of Tadalafil for 3 months and compared to Placebo
Study NCT05213884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200 mg, intravenous infusion over 30 minutes (Q3W); 1\~3 cycles of camrelizumab before radiotherapy and camrelizumab are maintained for 16 cycles (1 year) after the end of radiotherapy.